Branford’s CAS Medical Systems Inc. says it won federal clearance to broaden use of its patented blood-oxygen measurement device to monitor oxygen levels throughout the bodies of critically ill babies and youths.
The federal Food and Drug Administration approved CAS Med’s labeling of its Fore-Sight brand tissue oximeter, developed to non-invasively monitor blood-oxygen levels in patient’s brains, for use on the skeletal muscles of infants, children and adolescents weighing from 11 to 110 pounds (5 to 50 kilograms.)
The FDA clearance broadens the clinical applications, as well as medical customers, for the Fore-Sight device in clinical settings, said CAS Med CEO Thomas M. Patton.
Low oxygen levels in tissue are associated with, among other things, stroke, weak heart function and shock.
In early afternoon trading, CAS Med’s stock was up 20 cents, or 6.3 percent, to $3.40.
